Milrinone-Induced Cardiac Arrhythmias
Milrinone causes both ventricular and supraventricular arrhythmias, with ventricular ectopy being most common (occurring in 12.1% of patients), including nonsustained ventricular tachycardia (2.8%), sustained ventricular tachycardia (1%), and ventricular fibrillation (0.2%). 1
Specific Arrhythmias Documented
Ventricular Arrhythmias (Most Common)
- Ventricular ectopic activity/PVCs: 8.5% incidence 1
- Nonsustained ventricular tachycardia: 2.8% 1
- Sustained ventricular tachycardia: 1% 1
- Ventricular fibrillation: 0.2% 1
- Torsades de pointes: Rare but documented in post-marketing surveillance 1
Supraventricular Arrhythmias
- Overall supraventricular arrhythmias: 3.8% incidence 1
- Atrial fibrillation/flutter: Documented in multiple studies 2, 3
- New-onset atrial arrhythmias: More frequent with milrinone versus placebo (4.6% vs 1.5%, p<0.004) in the OPTIME-CHF trial 2
Pediatric Population
In children undergoing congenital heart surgery, milrinone independently increases the odds of clinically significant tachyarrhythmias by 2.8-fold (95% CI 1.3-6.0, p=0.007), with common arrhythmias including:
- Monomorphic ventricular tachycardia (12%)
- Junctional ectopic tachycardia (10%)
- Accelerated junctional rhythm (8%)
- Atrial tachyarrhythmias (8%) 4
Critical Clinical Context
The arrhythmogenic risk is NOT dose-dependent - the incidence of both supraventricular and ventricular arrhythmias has not been related to dose or plasma milrinone concentration 1. This makes titration ineffective as a risk mitigation strategy.
High-Risk Scenarios
Arrhythmias are more likely when milrinone is combined with:
- Pre-existing arrhythmias
- Metabolic abnormalities (especially hypokalemia)
- Abnormal digoxin levels
- Recent myocardial infarction (2-4 days post-MI shows highest risk) 5
- Ischemic heart failure etiology (post-hoc analysis showed higher death/rehospitalization) 2
Mechanism
Milrinone inhibits phosphodiesterase-3, increasing intracellular cAMP and calcium availability. This:
- Shortens atrial action potential duration
- Accelerates spontaneous firing
- Triggers delayed afterdepolarizations at pulmonary veins
- Increases ventricular ectopy through enhanced calcium cycling 3
Monitoring Requirements
Continuous cardiac monitoring is mandatory during milrinone infusion 1. The FDA label explicitly states patients should be "closely monitored during infusion" with particular attention to:
- Blood pressure and heart rate (infusion should be slowed or stopped with excessive hypotension)
- Electrolytes, especially potassium (hypokalemia predisposes digitalized patients to arrhythmias)
- Renal function (though renal impairment alone does not increase arrhythmia risk) 6
Important Caveat
Milrinone produces slight shortening of AV node conduction time, potentially increasing ventricular response rate in patients with atrial flutter/fibrillation not controlled with digitalis 1. These patients require particularly vigilant monitoring.
Contraindications and Warnings
The 2013 Canadian guidelines explicitly state that milrinone increased new-onset atrial arrhythmias, worsening heart failure, and symptomatic hypotension in the OPTIME-CHF trial, with a nonsignificant increase in deaths 2. The 1995 ACC/AHA guidelines note concerns about safety given increased mortality with long-term milrinone therapy 7.
Milrinone should not be used in acute myocardial infarction - no clinical studies support its use in this population, and it is not recommended until further experience is gained 1.